Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.

Nutriband Inc. announced it has received a Notice of Allowance from the USPTO for its patent application regarding the Aversa™ abuse deterrent technology, which is designed to prevent the misuse and ...

Nutriband granted patent protecting its AVERSA abuse deterrent platform technology in Macao, a Special Administrative Region of the People’s Republic of China ORLANDO, Fla., April 11, 2025 (GLOBE ...

Canadian Patent Enhances Market Exclusivity and Licensing Potential Expands Global Intellectual Property Portfolio Supporting Long-Term Revenue Growth VANCOUVER, BC / ACCESS Newswire / / Ovation ...

Love Pharma has struck a deal to acquire transdermal drug delivery technology, signing a letter of intent to buy Naltrexone Therapeutics for intellectual property covering the administration of a ...

Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid ...

ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including ...

Independent Report Examines Collagen Patch Benefits, Delivery Science, and What Consumers Evaluate — With Invig+ as Category ReferenceNEW YORK, NY, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This ...

Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband (NTRB) is targeting to file for FDA approval for AVERSA™ ...